Full-Time
AI User Enablement & Adoption Specialist
Posted on 8/19/2025
RA Capital Management
Invests in healthcare, life sciences.
No salary listed
No H1B Sponsorship
Boston, MA, USA
Hybrid
 IT & Security (1) |
|---|
- Bachelor's degree in Information Technology, Learning & Development, Communications, Business Administration, or a related discipline
- 5 - 8 years of experience in project management, technology adoption, user enablement, training, change management, or a similar role
- Demonstrated practical experience and strong understanding of Enterprise AI tools (e.g., ChatGPT, Claude, Google Gemini, Glean, etc.) and emerging vibe coding platforms (e.g. Lovable, Replit, etc.) and their application in a professional setting
- Excellent communication, presentation, and interpersonal skills, with the ability to translate complex technical concepts into clear, understandable language for non-technical audiences
- Strong empathy for users and a passion for improving the end-user experience with technology
- Proven ability to design and deliver effective training programs and create compelling instructional content
- Experience with user support, troubleshooting, and problem-solving in a fast-paced environment
- Ability to work independently and collaboratively in a dynamic, cross-functional team environment
- Proactive, self-starter with a continuous learning mindset
- Must be based in Boston with ability to work a hybrid schedule in our downtown Boston office
- Must be authorized to work in the United States without sponsorship
- AI User Enablement Strategy: Support and execute the strategy for AI adoption across the firm, focusing on general-purpose AI tools (e.g., large language models, image generation, summarization tools) and their integration into daily workflows
- Training & Education: Design, develop, and deliver engaging training programs, workshops, and educational materials tailored to various user groups and their skill levels. This includes introductory sessions, advanced prompt engineering techniques, ethical AI usage, and best practices for leveraging AI tools in a financial services context
- Content Creation: Create and maintain a centralized repository of both internal and external/public resources, including quick-start guides, FAQs, video tutorials, and internal success stories, to promote self-service and continuous learning
- User Support & Guidance: Provide hands-on support and guidance to end-users, troubleshooting common issues, answering questions, and offering personalized coaching to help them effectively integrate AI into their tasks and workflows
- Friction Reduction & Workflow Integration: Collaborate with IT and business teams to identify and address user friction points related to AI tools, advocating for user experience improvements and seamless integration into existing communication and collaboration platforms
- Community Building: Foster an internal community of AI champions and early adopters, facilitating knowledge sharing, peer-to-peer learning, and the identification of new, impactful use cases for AI within the firm
- Stay Current & Inform: Continuously monitor the evolving landscape of AI tools and trends, evaluating new features and applications. Communicate relevant updates and potential opportunities to users and stakeholders
- Feedback & Optimization: Gather user feedback through surveys, focus groups, and direct interactions to identify areas for improvement in AI tools, training, and support, driving continuous optimization of the AI user experience
- Collaboration with IT & Data Teams: Work closely with the broader IT, Data, and AI development teams to align enablement efforts with strategic AI initiatives and ensure security and compliance best practices are maintained
- Ethical AI Use: Promote and reinforce the firm's compliance guidelines and best practices for responsible and ethical AI use, including, data privacy, confidentiality, and bias awareness
- Experience with specific collaboration and communication platforms used at RA Capital (e.g. Glean, Retool, Notebook LM, Lovable, Replit, v), Bolt.new, Claude Code, and other workflow automation tools
- Familiarity with change management methodologies (e.g., PROSCI ADKAR)
- Experience in the financial services industry
- Understanding of data governance, security, and compliance principles, especially within a regulated industry
- RA Capital is an equal opportunity employer. We are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status. If you require an accommodation during the interview process, please reach out to [email protected] for assistance.
RA Capital Management channels capital and expertise into healthcare, life sciences, and planetary health companies across growth stages. It funds ventures from private seed rounds to public follow-ons and uses evidence-based investing to guide decisions. Its TechAtlas research engine and Raven incubator provide internal data and a collaborative platform for entrepreneurs to develop and commercialize ideas. The firm aims to grow value for its portfolio and stakeholders by supporting companies that advance health outcomes, managing over $10 billion in assets.
Company Size
N/A
Company Stage
N/A
Total Funding
$37.9B
Headquarters
Boston, Massachusetts
Founded
2001
Simplify's Take
What believers are saying
- Contraline's $92.5 million Series B deepens exposure to reproductive-health innovation.
- Secretome's $30 million Series A targets Duchenne cardiomyopathy with few treatment options.
- Eighty-five disclosed holdings broaden access to pipeline-readouts and follow-on opportunities.
What critics are saying
- Contraline's NES/T Gel faces binary safety, efficacy, and FDA approval risk.
- Secretome's STM-01 remains pre-commercial, with severe translational risk before pivotal trials.
- Broad healthcare exposure can dilute focus when capital chases multiple stage-specific programs.
What makes RA Capital Management unique
- Evidence-based healthcare investing remains RA Capital's core strategy.
- It operates as a multi-stage investor across private and public healthcare.
- Peter Kolchinsky leads a platform spanning drugs, devices, diagnostics, and research tools.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at RA Capital Management who can refer or advise you
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Company News
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]
Adcendo, a Copenhagen-based biotech company developing antibody-drug conjugates for cancer treatment, has raised $75 million in an oversubscribed Series C round led by Jeito Capital. Vida Ventures, BPI France and EIFO joined as new investors, alongside existing backers including TCGX, RA Capital Management, TPG and Novo Holdings. The funding will support clinical milestones for Adcendo's pipeline, including the ADCE-T02 Phase I study in multiple tumour types, the ADCE-D01 study in soft tissue sarcoma and the ADCE-B05 study in squamous cell carcinomas. The company is advancing three antibody-drug conjugates targeting cancers with high unmet medical needs. Ksenija Pavletic from Jeito Capital and Rajul Jain from Vida Ventures will join Adcendo's board of directors.
Incyclix Bio has raised an additional $5 million in its Series B financing round from Hatteras, bringing new support to advance its clinical trial of INX-315. The novel CDK2 inhibitor targets patients with CDK4/6 inhibitor-resistant ER+/HER2- breast cancer or CCNE1-amplified solid tumours. The funding will support clinical development of INX-315 for treating advanced and metastatic breast and ovarian cancer. Hatteras joins existing Series B investors including Boxer Capital, RA Capital Management, Eshelman Ventures, Eli Lilly and Company, Pharmacosmos and Cape Fear BioCapital. The Phase 1/2 open-label dose-escalation and expansion trial of INX-315 is currently ongoing. Kseniya Simpson and Christy have joined Incyclix Bio's board following the investment.
Neurocrine bids $2.9B for Soleno with Vykat in PWS. April 6, 2026 Neurocrine Biosciences Inc. is making a play to take over Soleno Therapeutics Inc. for $53 per share in cash, which works out to an equity value of $2.9 billion. If it goes through, the move will add Vykat XR (diazoxide choline), a first-in-class therapy to treat hyperphagia, the defining feature of Prader-Willi syndrome, to San Diego-based Neurocrine's hopper. Since its U.S. FDA clearance and the launch in the second quarter of last year, Vykat has generated $190 million in 2025 revenue, including $92 million for Soleno, of Redwood City, Calif., in the fourth quarter alone. Shares of Soleno (NASDAQ:SLNO) were trading at $52.20, up $12.71, or 32%. Neurocrine's stock (NASDAQ:NBIX) was selling for $129.38, down $2.22. Sector tariff now more than a threat - for some rx companies. After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump delivered it late last week. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. However, depending on the drug, where it's made and whether a manufacturer has reached onshoring and pricing agreements with the Department of Health and Human Services, the actual tariff could be as low as 0%. Regardless, the timing could hardly be worse. Stipple launches with $100M for novel oncology targets. Stipple Bio Inc. raised $100 million in a series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest. The company was founded by Aaron Ring at Fred Hutchinson Cancer Center and Aashish Manglik at University of California, San Francisco, to identify novel epitopes expressed on tumor cells with limited expression on healthy tissue. Rather than focusing on targets that are over-expressed, Stipple's Pointillist platform looks for post-translational modifications, protein conformation changes or mis-location of proteins that lead to epitopes that are specific to cancer cells. The Cambridge, Mass.-based company expects to have its lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, in the clinic in early 2027. Circuit split forming over state 340B laws. Do state laws requiring drug companies to give steep 340B drug discounts to an unlimited number of contract pharmacies, with no claims data required, interfere with a longstanding contract between the U.S. Congress and biopharma? Or do such laws merely flex states' authority over pharmacy practices such as delivery? Those questions are at the heart of a new circuit split, which could eventually take the dispute to the Supreme Court. One-carbon has new approach to starving tumors of nucleotides. Swedish startup One-carbon Therapeutics AB is going after solid tumors with an approach that looks similar to synthetic lethals to some people, and to chemotherapy to others. But One-carbon CEO Ana Slipicevic said that TH-9619, the company's first-in-class inhibitor of the enzyme MTHFD1/2, is neither of those things. Slipicevic told BioWorld that there are some similarities to the synthetic lethal approach, in that TH-9619 targets a pathway that cancer cells are uniquely vulnerable to, and works in part by preventing them from repairing their DNA. Another similarity is that like PARP inhibitors, which are the icon of synthetic lethal targeting, MTHFD1/2 inhibition originated in the lab of Thomas Helleday. "We are a spin-off from Karolinska [Institute], and [MTHFD inhibition] went through a lot of early work in academia before we took over," Slipicevic said. Biopharma financings nearly double vs. 2025 to $25.1B. Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024. Holiday notice. BioWorld's offices were closed in observance of Good Friday. No issue was published April 3. Also in the news. Adagene, Akebia, Alto, Arcellx, Arch, Astrazeneca, Axsome, Beam, Boston Scientific, BSM, Celldex, Clarametyx, Cocrystal, Context, Coya, Curve, Eli Lilly, Ellipsys Medical, Entera, Fore, Gilead, Harmony, Hoth, Immunovant, Incyte, Inovio, Lipocine, Lupin, MDIC, Merck, Neutrolis, Novo Nordisk, Oncotelic, Orionis, Pangia, Pavmed, Puretech, Seaport, Shionogi, Soligenix, Stairmed, Tanabe, Techforce Robotics, Telix, Tenpoint, Ultragenyx, Valencia, Vascarta, Visufarma, Zeto To read more on related topics, click on one of the words below.
Stipple Bio emerges from stealth with $100M Series A to advance STP-100 ADC and Pointillist epitope platform.